NL-OMON31776已完成不适用
An Evaluation of a Doppler-Guided Uterine Artery Occlusion Device (D-UAO) as Treatment for the Reduction of Fibroid-Associated Symptoms - The D-UAO study
ETHICON _ Johnson & Johnson MEdical Ltd0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.25 to 50 years of age;2.Subject has a negative pregnancy test prior to the procedure. At the time of enrolment to the study, the subject has no intent of further childbearing and intends to use appropriate contraception throughout the first 12-months of the study period (unless sterilized);3.Normal pap smear within 36 months of study procedure;4.Normal endometrial biopsy within 36 months of study procedure;5.Cervix suitable for tenaculum placement as determined by pelvic exam (adequate length of cervix, absence of cervical fibroid/lower fibroid to prevent clamp placement); 6.At least one intra-mural uterine fibroid of greater than or equal to 3cm, and all fibroids with a diameter less than or equal to 8cm with a prevailing pathology (e.g., as opposed to adenomyosis) of fibroids determined through ultrasound; 7.Subject agrees to participate in the study, including completion of all study-related procedures and evaluations, and documents this agreement by signing the EC-approved informed consent.
排除标准
- •1.Pregnancy as confirmed by positive urine pregnancy test; 2.Menopausal as defined by elevated follicle-stimulating hormone (FSH) and oestradiol hormone levels as determined by the hospital local laboratory reference range criteria;3.Presence of an intra-uterine device (IUD);4.Presence of only sub-mucosal fibroids or any pedunculated fibroids as determined by MRI, ultrasound or hysteroscopy; 5.Severe hydronephrosis as determined on renal ultrasound pre-procedurally; 6.Clinical history of any thromboembolic disease;7.Blood Urine Nitrogen (BUN) greater than 7.2mmol/L* and/or serum creatinine greater than 106*mol/L* unresolved with change in diet or hydration; 8.History of gynecologic malignancy, atypical endometrial hyperplasia, or chronic pelvic inflammatory disease;9.Pelvic mass outside the uterus other than uterine fibroids;10.Any current acute or chronic systemic infection or localized pelvic infection, including a urinary tract infection;11.Use of GnRH agonist or mifepristone within 6-months prior to the start of the study procedure unless used immediately prior to the procedure. 12.Using anticoagulation therapy (except over the counter treatments (e.g. aspirin)), or have an underlying bleeding disorder; 13.Unsuitable for MRI examination (e.g. severe claustrophobia, non-MRI-compatible implanted metalloid devices)14.Prior endometrial ablation, uterine artery embolisation, or uterine artery ligation;15.Poor procedural candidate due to medical conditions as determined by the investigator (e.g. anesthesia class, renal insufficiency, heart disease); and 16.If applicable, Grade 1 (no flow visualized) on ureter flow assessment. *or above applicable local lab normal values
研究者
相似试验
终止
不适用
Uterine Artery Occlusion for Fibroid Related BleedingUterine FibroidsMenorrhagiaNCT00496067Ethicon, Inc.91
终止
不适用
Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related BleedingUterine FibroidsMenorrhagiaNCT00496080Ethicon, Inc.87
尚未招募
不适用
Testing the Accuracy of Uterine Artery Doppler in detecting endometrial abnormalities in women with peri and post menopausal bleedingCTRI/2021/04/033089Dr Rashmi Natarajan
尚未招募
不适用
Comparison of uterine artery Doppler during the second trimester of pregnancy between women with and without history of prior caesarean deliveries and its effect on perinatal outcomeTCTR20230529002Bhumibol Adulyadej Hospital590
尚未招募
Unknown
Effect of Ovarian endometrioma on blood flow in uterine and ovarian arteries and oocyte qualityCTRI/2024/06/069159ot applicable